Media
Check out our latest corporate updates, features in the media, and scientific publications and presentations.
Media
- Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies
- CAN-2409/Vancyclovir Leads to Positive Tolerability, Immune Response in NSCLC
- Viral Immunotherapy Combo Improves Survival in Patients With NSCLC
- Dr. Paul Peter Tak, MD, PhD – Developing Novel Viral Immunotherapies To Improve Cancer Outcomes with Ira Pastor of Progress, Potential, and Possibilities Podcast
- Candel Therapeutics President and CEO Interviw with Investment Reports
- Candel Therapeutics (NASDAQ: CADL) Interview with Wall Street Analyzer
- Just Two Years at the Helm, CEO Paul Peter Tak Transforms Candel and Cancer Therapy
- Jason Amello, CFO at Candel, Discusses Plans for New Role
- Candel’s New CMO Aims to Advance Cancer Portfolio
- Candel Pairs HSV Vectors with Carl June’s CAR-T Cells in Solid Tumor Pact (Updated)
- Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge
- Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics
- Candel’s CEO looks to help ignite a new era of cancer treatments
- After flicker, investor enthusiasm for Candel burns brighter
- Newly public Candel looks to two years of value inflection points
- Candel Therapeutics, Inc NASDAQ Bell Ringing
- After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player
- Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets
- Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline
2024
American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Overall survival after treatment with CAN-2409 plus valcyclovir in combination with continued ICI in patients with Stage III/IV NSCLC with inadequate response to ICI
Charu Aggarwal, MD, MPH
Longitudinal sterotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM); David Reardon, MD
American Association for Cancer Research (AACR) Annual Meeting 2024
A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors
Francesca Barone, MD, PhD
2023
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Neoadjuvant CAN-2409 + Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC)
W. Garrett Nichols, MD, MS
Development of enLIGHTEN Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
Francesca Barone, MD, PhD
A novel viral immunotherapeutic targeting the CD47/SIRPa axis demonstrates potent anti-tumor effects
Anne R. Diers, PhD
American Society of Clinical Oncology (ASCO) Annual Meeting 2023
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC
Charu Aggarwal, MD, MPH
26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Safety and survival outcomes in recurrent high-grade glioma patient treated with CAN-3110, a first-in-class ICP34.5 expressing oncolytic HSV1
Francesca Barone, MD, PhD
37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Patrick Y. Wen, MD
Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice
Anne R. Diers, PhD
American Society of Clinical Oncology (ASCO) Annual Meeting 2022
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
Charu Aggarwal, MD, MPH
Publications
Ling AL et al. Nature (2023)
Perturbing Clinical trials links oncolytic immunoactivation to survival in glioblastoma.
Publication
Koch MS et al. Molecular Therapy Oncolytics (2022)
Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.
Publication
Koch MS et al. Journal for ImmunoTherapy of Cancer (2022)
J Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Publication
Rahman et al. The Lancet Oncology (2021)
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Publication
Predina et al. Molecular Therapy (2020)
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Publication
Kieran et al. Neuro-Oncology (2019)
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Publication
Aggarwal et al. Molecular Therapy (2018)
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
Publication
Speranza et al. Neuro-Oncology (2018)
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Publication
Wheeler et al. Neuro-Oncology (2016)
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Publication
Aguilar et al. Cancer Immunology, Immunotherapy (2015)
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Publication
Candel Therapeutics Announces Pricing of Initial Public Offering
Press ReleaseCandel Therapeutics Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
Press ReleaseCandel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference
Press ReleaseCandel Therapeutics Names Carrie S. Cox as Chairman of its Board of Directors
Press ReleaseCandel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas
Press ReleaseCandel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
Press ReleaseCandel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
Press ReleaseCandel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments
Press ReleaseCandel Therapeutics Announces Presentation of Clinical Data for GMCI in NSCLC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics Announces Presentation at the 2020 American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting
Press ReleaseCandel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise
Press Release